A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapy

Chimeric antigen receptor (CAR) T cell immunotherapy is promising for treatment of blood cancers; however, clinical benefits remain unpredictable, necessitating development of optimal CAR T cell products. Unfortunately, current preclinical evaluation platforms are inadequate due to their limited phy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Chao, Wang, Huishu, Liu, Lunan, Tong, Jie, Witkowski, Matthew T., Aifantis, Iannis, Ghassemi, Saba, Chen, Weiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153390/
https://www.ncbi.nlm.nih.gov/pubmed/37131801
http://dx.doi.org/10.21203/rs.3.rs-2762929/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153390/
https://www.ncbi.nlm.nih.gov/pubmed/37131801
http://dx.doi.org/10.21203/rs.3.rs-2762929/v1

Ejemplares similares